公司資料

Veru Inc 股價、新聞與催化劑

股票代碼:: VERU
交易所:: NASDAQ
產業:: Biopharma
所在地:: United States

股票表現

2.63 USD (-3.66%)

收盤價

最後更新: 2026年8月17日

37.7M USD

市值

股價為何變動

As of Aug 17, 2026, VERU closed down 3.66% at $2.63. No new same-company headline was identified in the current news window.

公司概覽

Cardiometabolic and Inflammation Company

Veru develops late-stage small molecules for cardiometabolic and inflammatory diseases.

Enobosarm

Enobosarm is an oral selective androgen receptor modulator being evaluated to preserve lean mass, physical function, and bone health during GLP-1-driven weight loss in older adults with obesity.

PLATEAU Study

The Phase 2b PLATEAU study combines enobosarm with semaglutide and measures body composition, weight, function, and safety.

未來催化劑

Interim lean-mass and fat-mass analysis from the Phase 2b PLATEAU study in the first quarter of 2027.
Final topline results from the Phase 2b PLATEAU study in the fourth quarter of 2027.